Michael R. Jirousek
Michael R. Jirousek holds a Ph.D. degree in chemistry from Case Western Reserve University, Cleveland, Ohio, USA, and was a Postdoctoral Fellow at Harvard University. Jirousek, Catabasis Cofounder and Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development. Prior to joining Catabasis, he was a Corporate Officer and a Senior Vice President of research at Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), where he was the Head of research for the company. His team produced several first-in-class SIRT1 modulators that are in phase 1 and 2 studies, with additional compounds in IND-enabling toxicology studies. He joined Sirtris from Pfizer La Jolla, part of Pfizer Global Research and Development, where he was a Senior Director and the Head of the metabolic therapeutic area. Dr. Jirousek founded the La Jolla group, growing the effort over the course of five years into a highly productive team that produced six clinical candidates. Prior to joining Pfizer, Dr. Jirousek was the Department Head at Abbott Laboratories for three years. In this role, he focused on discovering and developing new agents to overcome leptin and insulin resistance, of which several clinical candidates resulted from his groups' programs. Dr. Jirousek spent eight productive years at Eli Lilly in Indianapolis and Hamburg, Germany, focusing on diabetic complications and PKC inhibitors. He also worked in the field of small molecule approaches to improve islet function and mimics of GLP-1 action. Throughout his career in drug discovery and development, Dr. Jirousek has been responsible for coinventing and/or bringing 12 compounds from inception into clinical trials as potential new therapeutics to treat cancer, obesity, diabetes, and diabetic complications. He has coauthored more than 170 peer-reviewed papers, abstracts, and patents.
Biography Updated on 5 March 2012